Public release date: 15-Nov-2012 [ | E-mail | Share ] Contact: Michael C. Purdy purdym@wustl.edu 314-286-0122 Washington University School of Medicine Insights from a genetic condition that causes brain cancer are helping scientists better understand the most common type of brain tumor in children. In new research, scientists at Washington University School of Medicine in St. Louis have identified a cell growth pathway that is unusually active in pediatric brain tumors known as gliomas. They previously identified the same growth pathway as a critical contributor to brain tumor formation and growth in neurofibromatosis-1 (NF1), an inherited cancer predisposition syndrome. "This suggests that the tools we've been developing to diagnose and treat NF1 may also be helpful for sporadic brain tumors," says senior author David H. Gutmann, MD, PhD, the Donald O. Schnuck Family Professor of Neurology. The findings appear Dec. 1 in Genes and Development. NF1 is among the most common tumor predisposition syndromes, but it accounts for only about 15 percent of pediatric low-grade gliomas known as pilocytic astrocytomas. The majority of these brain tumors occur sporadically in people without NF1. Earlier research showed that most sporadic pilocytic astrocytomas possess an abnormal form of a signaling protein known as … Continue reading →

Editor's Choice Main Category: Urology / Nephrology Also Included In: Pediatrics / Children's Health;Genetics Article Date: 16 Nov 2012 - 10:00 PST Current ratings for: Genetic Link Found In Children With Kidney Defects And Neurodevelopmental Disorders Around 10 percent of kids with kidney defects have these mutations in their genomes, also known to be associated with mental illness and neurodevelopmental delay. Congenital urinary tract and kidney defects make up about 25 percent of all birth defects in the United States and are found in one in every 200 births. At last, an analysis for genomic alterations will be included in standard clinical workup. Patients who have congenital kidney disorder, presently included in one group, will be put into subcategories according to their genetic mutations, resulting in a more specific diagnosis. Kidney specialist Ali Gharavi, MD, associate professor of medicine at CUMC, associate director of the Division of Nephrology, and an internist and nephrologist at NewYork-Presbyterian Hospital says: This study was a broad collaboration of CUMC and other medical centers worldwide. Up until this point, no studies have successfully connected congenital kidney disease with neurodevelopmental disorders. Simone Sanna-Cherchi, MD, an associate research scientist in CUMC's Department of Medicine explains: Nearly 20 … Continue reading →

A patient receives an ultrasound before a new genetic test for potential fetus abnormalities Oct. 4 at obstetrician Susan Klugman's office in Scarsdale, N.Y.(Photo: Carucha L. Meuse, The (Westchester, N.Y.) Journal News) WESTCHESTER, N. Y. -- A new test, called chromosomal microarray technology, is providing doctors and prospective parents with more information than ever before about the genetic makeup of a baby still in the womb. But what that knowledge actually means is not always clear, causing confusion and anxiety for parents and physicians. Michelle Catalano had no reason to think her fourth baby wouldn't be born as healthy as her other three. But because the Eastchester, N.Y., resident was 36 -- a year into the territory obstetricians ominously describe as "advanced maternal age" -- she was given the option of using the new technology to test whether her baby was developing free of genetic defects that could signal trouble. "It's an evolving technology," said David Kronn, chief of medical genetics at Maria Fareri Children's Hospital at Westchester Medical Center in Valhalla, N.Y. The results, he said, aren't always cut and dried. Susan Klugman, an obstetrician in Larchmont and Yonkers, N.Y., and 300 of her patients recently took part in … Continue reading →

Mrs. Linda Flournoy describes ger experience with Stem Cell Therapy PRPFrom:FLRegenerativeMedViews:14 0ratingsTime:02:27More inEducation Read this article: Mrs. Linda Flournoy - Video … Continue reading →

A year after announcing its decision to exit stem cell therapy, Geron Corporation (GERN) announced that it has entered into a non-binding letter of intent (:LOI) with BioTime, Inc. (BTX) and BioTime`s subsidiary, BioTime Acquisition Corporation (BAC), regarding the stem cell program. According to the LOI, Geron will provide BAC with the intellectual property and other assets related to its discontinued human embryonic stem cell programs. BioTime will provide BAC with cash ($5 million), shares ($30 million), warrants to purchase 8 million shares at a pre-determined price, rights to use certain human embryonic stem cell lines, and minority stakes in two subsidiaries of BioTime. Meanwhile, Geron stockholders would have a 21.4% stake in BAC along with warrants to purchase 8 million shares at a pre-determined price. Geron would also be entitled to receive royalties on the sale of products covered by the patents acquired by BAC from Geron. Apart from Geron, BioTime would have a 71.6% stake in BAC and the remaining 7% would be owned by a private investor (for an investment of $5 million). BioTime will also have warrants which would allow the company to increase its stake in BAC by 2%. However, this would lead to a … Continue reading →

Stem Cell Therapy | Stem Cell Malaysia stemcellmalaysia.com Stem cell therapy is a form of cell therapy that makes use of stem cells harvested from placenta for disease treatment. Stem cell therapy is also used for beauty, anti-aging and health rejuvenation purposes. The efficacy of stem cell therapy has been in practice for decades. Many rich and wealthy individuals and celebrities pay hefty price for stem cell therapy just to maintain youthfulness and vitality. For many severely ill-stricken people who have exhausted all means of conventional therapy look toward stem cell therapy for saving their condition and life. stemcellmalaysia.comFrom:stemcells2012Views:317 3ratingsTime:07:23More inHowto Style Read this article: Stem Cell Therapy | Stem Cell Malaysia - Video … Continue reading →

Mrs. Linda Flournoy describes ger experience with Stem Cell Therapy PRPFrom:FLRegenerativeMedViews:2 0ratingsTime:02:27More inEducation See the article here: Mrs. Linda Flournoy - Video … Continue reading →

Video 7 - November 14, 2012 - Adult Stem Cells Progress.wmv Breif interview of my progress with Multiple Sclerosis with Adult Stem Cell therapy after my experience with Tysabri, Gilenya and Ampira failed.From:MSajourneyfromwithinViews:1 0ratingsTime:04:21More inEducation Excerpt from: Video 7 - November 14, 2012 - Adult Stem Cells Progress.wmv - Video … Continue reading →

For Dr. Robert Janson-Mller, the science of fresh cell therapy is in his blood. His grandfather, Dr. Philipp Janson was one of the few doctors who introduced the treatment in Germany. His father, Dr. Wolfgang Janson-Mller continued the work that was eventually passed on to him. He was exposed to the revolutionary world of fresh cell therapy early on in life. The treatment uses live young cells from a donor animal like sheep to help regenerate damaged cells in the body. Dr. Mller practically grew up in his grandfather and father's clinic where he met the former's patients, some of whom still go to him for their regular treatments. ''A child always wants to grow up like his father and do the same thing. My father left it open for me. He told me I could do whatever I want, the same thing I am doing now for my daughter. I'm also head of a clinic in Munich. This is what I do besides cell treatment. We have a family practice. That is my main job,'' shares the 46-year-old German doctor who recently visited the Philippines to acquaint Filipinos with the science of fresh cell therapy. Dr. Mller, who owns … Continue reading →